Close Menu

Lucence Diagnostics LiquidHallMark

Oct 24, 2018

Lucence Diagnostics launched the LiquidHallMark blood test for detecting multiple cancer-related mutations and viral targets for clinical use in Asia. Physicians can use the test to select targeted therapies and to monitor treatment response. The liquid biopsy panel identifies clinically relevant genomic alterations including somatic mutations, microsatellite instability, and viral DNA from ctDNA in blood. It was developed for cancers that are particularly prevalent in Asia, such as breast, colon, lung, and nasopharyngeal cancers. The test is based on Lucence's proprietary technology called AmpliMark that has sensitivity and specificity of up to 99.9 percent, the company said. 

More Like This

Jun 18, 2019

Biocept NGS Breast Panel

Biocept has launched its second multi-gene liquid biopsy product, the Target Selector NGS Breast Panel, which is run on Thermo Fisher Scientific's Ion Torrent next generation sequencing platform and is designed to enable the detection and monitoring of actionable genomic biomarkers associated with breast cancer. The company said the test, which will be marketed to physicians and researchers, has shown over 99 percent sensitivity with at least 90 percent specificity in internal validations. 

Jun 17, 2019

Qiagen Microbial Insights AR

Qiagen has launched Microbial Insights AR (QMI-AR), an integrated genomic database that provides curated, single-point entry access to four of the world's largest knowledgebases on antimicrobial resistance. Specifically, it integrates the Comprehensive Antibiotic Resistance Database (CARD), ResFinder, and National Institutes of Health AMRFinder database of resistance genes, as well as the ARG-ANNOT database of peptide markers. This complements ARESdb, a comprehensive, regularly updated genomic knowledgebase on clinically relevant antibiotic resistance strains that Qiagen has made available to the global research community through a partnership with Ares-Genetics (a Curetis subsidiary). QMI-AR will initially be available through Qiagen's CLC Microbial Genomics Module, an extension to the CLC Genomics Workbench bioinformatics software.

Jun 17, 2019

GeneCast RUO Kits

Chinese liquid biopsy firm GeneCast has launched a set of research-use-only kits for BRAF, EGFR, and JAK2 mutation detection. The firm claims technical sensitivity for the BRAF assay as low as 0.0001 percent, and for the EGFR and JAK2 kits of 0.01 percent. The products use the company's ADPS quantitative PCR method, and the firm said it is working on gaining approval to offer the products for clinical use, filing a PMA submission with the US Food and Drug Administration, for the EGFR assay for example. GeneCast plans to launch additional RUO kits for KRAS, NRAS, PIK3CA, pTERT, IDH1, and IDH2 by the end of this year.


Jun 17, 2019

Twist Bioscience Mouse Core Exome Panel

Twist Bioscience has launched the Mouse Core Exome Panel for target enrichment in next-generation sequencing. The comprehensive panel for research use is built from the most current databases.

Jun 17, 2019

Paragon Genomics ClearPlex NGS Panels

Paragon Genomics has launched a series of CleanPlex products for MGI sequencers. The firm now offers its CleanPlex for MGI Ready-to-Use NGS panels, which can be used for both MGI's OncoZoom Cancer Hotspot Panel and MGI's BRCA1 and BRCA2 Panel. Paragon also offers its CleanPlex for MGI Custom NGS panels, which allow researchers to build customized assays to address specific needs. The firm noted that its support staff will take custom orders, developing and delivering panels that are completely compatible with MGISEQ sequencers. In addition, Paragon is offering validated automation protocols ensuring that CleanPlex for MGI assays can work with the MGISP-960 Automated Sample Preparation System to produce the same results performed if done manually. 

Jun 14, 2019

BGI Whole Exome Sequencing Service

BGI Genomics has launched a clinical research whole exome sequencing service called BGI-Xome, which incorporates clinical interpretation services from UK-based Congenica. BGI will perform WES at its service laboratories, while interpretation will be completed by clinical scientists using the Congenica clinical decision support platform. According to BGI, Congenica's Interpretation platform will allow its service to provide a "gold-standard" and effective solution that eliminates the risk of users missing or misidentifying disease-linked mutations. 

Jun 13, 2019

Oxford Gene Technology SureSeq NGS Library Prep Kit

Oxford Gene Technology has released a new SureSeq library preparation kit for hybridization-based target capture in next-generation sequencing. According to the firm, the kit offers a streamlined protocol with enrichment by hybridization with a ready-to-use hybridization and wash buffer. It also reduces manual handling steps to increase reliability and throughput. The firm also said that the kit lowers duplication rates, leading to more accurate calling and more even coverage.

Jun 12, 2019

Patients Choice Laboratories UTI+ Test

Patients Choice Laboratories has launched the UTI+ molecular test for urinary tract infections. The Indianapolis-based company said the new test is part of its goal to be a full-service lab. It added that its gene- and molecular-based technologies provides uropathogenic and antibiotic resistance testing results within six hours after specimen receipt compared to up to three days with urinalysis by culturing. 

Jun 11, 2019

Genestack Omics Data Manager

Genestack has introduced Omics Data Manager, a system for cataloguing, curating, indexing, searching, and sharing multi-omics data. Omics Data Manager can serve as centralized repository for enterprises looking to implement the FAIR (Findable, Accessible, Interoperable, and Reusable) principles for biomedical data management. Omics Data Manager can be integrated into laboratory information management systems and third-party, upstream data analysis platforms, according to Cambridge, UK-based Genestack. 

Jun 07, 2019

Thermo Fisher Scientific Orbitrap Exploris 480, Orbitrap Eclipse Tribrid Instruments and Mass Spectrometry Software

Thermo Fisher Scientific launched a number of mass spectrometry instruments and software this week.

The Thermo Scientific Orbitrap Exploris 480 mass spectrometer enables more rigorous high-throughput protein identification, quantitation, and structural characterization. It has a smaller footprint than previous instrument versions and maintains high resolution, mass accuracy, and spectral quality.

The Thermo Scientific Orbitrap Eclipse Tribrid mass spectrometer has improved sensitivity over previous generations and is better able to characterize and quantify complex biomolecules and biological systems.

Both new instruments can be combined with the Thermo Scientific FAIMS Pro interface, a differential ion mobility device that improves selectivity and increases productivity across a range of proteomics workflows.

The new Thermo Scientific TraceFinder Software 5.0 offers quicker and easier access to information from Thermo Scientific TSQ Quadrupole and Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometry platforms. In addition, the Thermo Scientific Almanac web-based application enables users to remotely access instruments to monitor their run status and data acquisition.

Jun 06, 2019

Arbor Biosciences MyNGS Guides MitoDeplete Kits

Arbor Biosciences, a division of Chiral Technologies, has launched MyNGS Guides MitoDeplete Kits as part of its catalog of guide RNA pools for targeted sequencing applications. This new depletion system combines Arbor's massively parallel, high-fidelity oligo synthesis platform with Cas enzymes for efficiently targeting unwanted molecules from NGS libraries. In-stock MitoDeplete catalog kits have been designed and validated for human and mouse applications, and the company can design and synthesize kits for other custom species on demand.

MitoDeplete kits are designed for use on any NGS library containing a significant percentage of mitochondrial DNA molecules, such as ATAC-Seq libraries. CRISPR-based depletion with MitoDeplete delivers up to a 95 percent reduction in mtDNA-derived molecules in a single-step process. The human and mouse kits are available for immediate shipment in an eight-reaction kit size. Kits for custom species can be produced on request through collaboration with one of the product scientists at Arbor.

Jun 06, 2019

Sciex TripleTOF 6600+ LC-MS/MS System

Sciex has launched the TripleTOF 6600+ LC-MS/MS System with ScanningSwath Acquisition alongside high-performance data processing with OneOmics in Sciex Cloud. The latest entry in Sciex's TripleTOF portfolio, the new platform incorporates simplified low-flow source technology to deliver accessible, sensitive and robust quantification; while multiple software-enabled improvements increase robustness and maximize system uptime, Sciex said.

Other features include OptiFlow Turbo V Source for all low-flow applications, with flow rates of 100 nL/min to 200 L/min; up to 100 Hz MS/MS scan speeds; and Analyst TF Software 1.8, which features scheduled ionization and target TIC function to give users temporal control over the number of ions entering the systems.

Sciex also introduced ScanningSwath Acquisition to be hosted on the system. This feature immortalizes samples by creating a digital data record of all detectable analytes, capturing more detail about potential markers than its predecessor, Sciex said.

Jun 04, 2019

Illumina VeriSeq NIPT Solution v2

Illumina has launched the VeriSeq NIPT Solution v2, a CE-IVD, next-generation sequencing-based approach to noninvasive prenatal testing. The new version expands the range of chromosomal and sub-chromosomal conditions associated with birth defects that laboratories can screen for. The assay provides information about fetal chromosomal status as early as 10 weeks of gestation using a single maternal blood draw, and provides an option to screen for aneuploidy in all autosomes, chromosomes X & Y, and partial deletions and duplications greater than 7 Mb across the genome. It is available in Europe and South Africa; registration is pending in Australia, Israel, and New Zealand.

Jun 04, 2019

Synthego Gene Knockout Kit v2

Synthego has launched its Gene Knockout Kit v2. The kit is based on a multi-guide strategy that employs up to three modified single guide RNAs targeting the same gene. These sgRNAs are spatially coordinated to reliably induce a fragment deletion of 21 or more base pairs. This intentional edit occurs at high frequency, increasing the probability of gene knockout, the company said. Each kit includes one tube of chemically modified multi-guide sgRNA, designed to target any human protein-coding gene, and the purchase of a kit includes free access to Synthego's ICE CRISPR Analysis Tool.

Jun 04, 2019

Tempus Integrated Molecular Evaluation (TIME) Trial

During this week's American Society of Clinical Oncology meeting, Tempus introduced Tempus Integrated Molecular Evaluation (TIME) Trial. This service features a proprietary technology platform that analyzes molecular and clinical data on cancer patients in real time to match people to clinical trials. TIME Trial only sends patients to prequalified academic and community cancer centers so those who qualify can enroll right away. 

The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.

The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.

Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.

In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.